Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers

Emicizumab (ACE910) is a bispecific antibody that is a novel, subcutaneously injectable treatment for patients with hemophilia A. This study assessed the relative bioavailability of emicizumab between old and new drug products (DPs) and among 3 commonly used subcutaneous injection sites (abdomen, up...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotani, Naoki, Yoneyama, Koichiro, Kawakami, Nobuhiko, Shimuta, Tohru, Fukase, Hiroyuki, Kawanishi, Takehiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767117/
https://www.ncbi.nlm.nih.gov/pubmed/30230257
http://dx.doi.org/10.1002/cpdd.617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767117/
https://www.ncbi.nlm.nih.gov/pubmed/30230257
http://dx.doi.org/10.1002/cpdd.617

Ejemplares similares